Why the study?
Does low-dose docetaxel and bisphosphonate prevent local recurrence or metastasis in a patient with MMP-9-expressing angiosarcoma?
Does low-dose docetaxel and bisphosphonate prevent local recurrence or metastasis in a patient with MMP-9-expressing angiosarcoma?
Low-dose docetaxel combined with a bisphosphonate may be an effective adjunctive treatment for MMP-9-expressing angiosarcoma following surgery and radiation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for adjunctive low-dose docetaxel plus bisphosphonate in MMP-9 angiosarcoma; leaves open efficacy pending prospective trials.
We describe a 78-year-old Japanese patient with angiosarcoma on the scalp. Interestingly, immunohistochemical staining revealed this tumor as positive for matrix metalloproteinase 9 (MMP-9). After conventional therapy for angiosarcoma with surgical treatment and radiation therapy, we intravenously administered docetaxel at 40 mg/m(2) body surface area together with oral administration of 17.5 mg sodium risedronate hydrate. One and a half years after the standard treatment, there was no evidence of local recurrence or metastasis.
No takes yet. Share an insight, caveat, or question.
Ishibashi et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: